Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Cuyàs E[au]:

Mitostemness. Cuyàs E et al. Cell Cycle. (2018)

Mitophagy-driven mitochondrial rejuvenation regulates stem cell fate. Vazquez-Martin A et al. Aging (Albany NY). (2016)

Metformin Potentiates the Benefits of Dietary Restraint: A Metabolomic Study. Riera-Borrull M et al. Int J Mol Sci. (2017)

Search results

Items: 1 to 50 of 71

1.

In silico clinical trials for anti-aging therapies.

Menendez JA, Cuyàs E, Folguera-Blasco N, Verdura S, Martin-Castillo B, Joven J, Alarcón T.

Aging (Albany NY). 2019 Aug 24;11(16):6591-6601. doi: 10.18632/aging.102180. Epub 2019 Aug 24.

2.

Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A.

Cuyàs E, Gumuzio J, Lozano-Sánchez J, Carreras D, Verdura S, Llorach-Parés L, Sanchez-Martinez M, Selga E, Pérez GJ, Scornik FS, Brugada R, Bosch-Barrera J, Segura-Carretero A, Martin ÁG, Encinar JA, Menendez JA.

Nutrients. 2019 Jul 19;11(7). pii: E1656. doi: 10.3390/nu11071656.

3.

Revisiting silibinin as a novobiocin-like Hsp90 C-terminal inhibitor: Computational modeling and experimental validation.

Cuyàs E, Verdura S, Micol V, Joven J, Bosch-Barrera J, Encinar JA, Menendez JA.

Food Chem Toxicol. 2019 Oct;132:110645. doi: 10.1016/j.fct.2019.110645. Epub 2019 Jun 26.

PMID:
31254591
4.

Computational de-orphanization of the olive oil biophenol oleacein: Discovery of new metabolic and epigenetic targets.

Cuyàs E, Castillo D, Llorach-Parés L, Lozano-Sánchez J, Verdura S, Nonell-Canals A, Brunet J, Bosch-Barrera J, Joven J, Valdés R, Sanchez-Martinez M, Segura-Carretero A, Menendez JA.

Food Chem Toxicol. 2019 Sep;131:110529. doi: 10.1016/j.fct.2019.05.037. Epub 2019 May 29.

PMID:
31150784
5.

Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients.

Cuyàs E, Fernández-Arroyo S, Buxó M, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Verdura S, Brunet J, López-Bonet E, Garcia M, Saidani S, Joven J, Martin-Castillo B, Menendez JA.

Aging (Albany NY). 2019 May 9;11(9):2874-2888. doi: 10.18632/aging.101960.

6.

A multiscale model of epigenetic heterogeneity-driven cell fate decision-making.

Folguera-Blasco N, Pérez-Carrasco R, Cuyàs E, Menendez JA, Alarcón T.

PLoS Comput Biol. 2019 Apr 30;15(4):e1006592. doi: 10.1371/journal.pcbi.1006592. eCollection 2019 Apr.

7.

The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin.

Cuyàs E, Buxó M, Ferri Iglesias MJ, Verdura S, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Joven J, Brunet J, López-Bonet E, Garcia M, Saidani S, Queralt Moles X, Martin-Castillo B, Menendez JA.

Front Oncol. 2019 Mar 28;9:193. doi: 10.3389/fonc.2019.00193. eCollection 2019.

8.

The extra virgin olive oil phenolic oleacein is a dual substrate-inhibitor of catechol-O-methyltransferase.

Cuyàs E, Verdura S, Lozano-Sánchez J, Viciano I, Llorach-Parés L, Nonell-Canals A, Bosch-Barrera J, Brunet J, Segura-Carretero A, Sanchez-Martinez M, Encinar JA, Menendez JA.

Food Chem Toxicol. 2019 Jun;128:35-45. doi: 10.1016/j.fct.2019.03.049. Epub 2019 Mar 29.

PMID:
30935952
9.

Intestinal Permeability Study of Clinically Relevant Formulations of Silibinin in Caco-2 Cell Monolayers.

Pérez-Sánchez A, Cuyàs E, Ruiz-Torres V, Agulló-Chazarra L, Verdura S, González-Álvarez I, Bermejo M, Joven J, Micol V, Bosch-Barrera J, Menendez JA.

Int J Mol Sci. 2019 Mar 31;20(7). pii: E1606. doi: 10.3390/ijms20071606.

10.

A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study.

Martin-Castillo B, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Stradella A, Morilla I, Viñas G, Cortés J, Cuyàs E, Verdura S, Fernández-Ochoa Á, Fernández-Arroyo S, Segura-Carretero A, Joven J, Pérez E, Bosch N, Garcia M, López-Bonet E, Saidani S, Buxó M, Menendez JA.

Oncotarget. 2018 Nov 2;9(86):35687-35704. doi: 10.18632/oncotarget.26286. eCollection 2018 Nov 2.

11.

Metformin Is a Direct SIRT1-Activating Compound: Computational Modeling and Experimental Validation.

Cuyàs E, Verdura S, Llorach-Parés L, Fernández-Arroyo S, Joven J, Martin-Castillo B, Bosch-Barrera J, Brunet J, Nonell-Canals A, Sanchez-Martinez M, Menendez JA.

Front Endocrinol (Lausanne). 2018 Nov 6;9:657. doi: 10.3389/fendo.2018.00657. eCollection 2018.

12.

An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors.

Verdura S, Cuyàs E, Lozano-Sánchez J, Bastidas-Velez C, Llorach-Parés L, Fernández-Arroyo S, Hernández-Aguilera A, Joven J, Nonell-Canals A, Bosch-Barrera J, Martin-Castillo B, Vellon L, Sanchez-Martinez M, Segura-Carretero A, Menendez JA.

Carcinogenesis. 2019 Mar 12;40(1):27-40. doi: 10.1093/carcin/bgy159.

PMID:
30428017
13.

Mitostemness.

Cuyàs E, Verdura S, Folguera-Blasco N, Bastidas-Velez C, Martin ÁG, Alarcón T, Menendez JA.

Cell Cycle. 2018;17(8):918-926. doi: 10.1080/15384101.2018.1467679. Epub 2018 Jul 2.

14.

Metformin directly targets the H3K27me3 demethylase KDM6A/UTX.

Cuyàs E, Verdura S, Llorach-Pares L, Fernández-Arroyo S, Luciano-Mateo F, Cabré N, Stursa J, Werner L, Martin-Castillo B, Viollet B, Neuzil J, Joven J, Nonell-Canals A, Sanchez-Martinez M, Menendez JA.

Aging Cell. 2018 Aug;17(4):e12772. doi: 10.1111/acel.12772. Epub 2018 May 8.

15.

Silibinin is a direct inhibitor of STAT3.

Verdura S, Cuyàs E, Llorach-Parés L, Pérez-Sánchez A, Micol V, Nonell-Canals A, Joven J, Valiente M, Sánchez-Martínez M, Bosch-Barrera J, Menendez JA.

Food Chem Toxicol. 2018 Jun;116(Pt B):161-172. doi: 10.1016/j.fct.2018.04.028. Epub 2018 Apr 14.

PMID:
29660364
16.

Epigenetic regulation of cell fate reprogramming in aging and disease: A predictive computational model.

Folguera-Blasco N, Cuyàs E, Menéndez JA, Alarcón T.

PLoS Comput Biol. 2018 Mar 15;14(3):e1006052. doi: 10.1371/journal.pcbi.1006052. eCollection 2018 Mar.

17.

Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells.

Corominas-Faja B, Cuyàs E, Lozano-Sánchez J, Cufí S, Verdura S, Fernández-Arroyo S, Borrás-Linares I, Martin-Castillo B, Martin ÁG, Lupu R, Nonell-Canals A, Sanchez-Martinez M, Micol V, Joven J, Segura-Carretero A, Menendez JA.

Carcinogenesis. 2018 Apr 5;39(4):601-613. doi: 10.1093/carcin/bgy023.

18.

Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity.

Cuyàs E, Verdura S, Fernández-Arroyo S, Bosch-Barrera J, Martin-Castillo B, Joven J, Menendez JA.

Oncotarget. 2017 Oct 15;8(59):99223-99236. doi: 10.18632/oncotarget.21834. eCollection 2017 Nov 21.

19.

Metformin Potentiates the Benefits of Dietary Restraint: A Metabolomic Study.

Riera-Borrull M, García-Heredia A, Fernández-Arroyo S, Hernández-Aguilera A, Cabré N, Cuyàs E, Luciano-Mateo F, Camps J, Menendez JA, Joven J.

Int J Mol Sci. 2017 Oct 28;18(11). pii: E2263. doi: 10.3390/ijms18112263.

20.

Metformin regulates global DNA methylation via mitochondrial one-carbon metabolism.

Cuyàs E, Fernández-Arroyo S, Verdura S, García RÁ, Stursa J, Werner L, Blanco-González E, Montes-Bayón M, Joven J, Viollet B, Neuzil J, Menendez JA.

Oncogene. 2018 Feb 15;37(7):963-970. doi: 10.1038/onc.2017.367. Epub 2017 Oct 23.

PMID:
29059169
21.

EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells.

Cuyàs E, Queralt B, Martin-Castillo B, Bosch-Barrera J, Menendez JA.

Oncol Rep. 2017 Jul;38(1):263-270. doi: 10.3892/or.2017.5682. Epub 2017 May 30.

PMID:
28560458
22.

BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.

Cuyàs E, Corominas-Faja B, Martín MM, Martin-Castillo B, Lupu R, Brunet J, Bosch-Barrera J, Menendez JA.

Oncotarget. 2017 May 23;8(21):35019-35032. doi: 10.18632/oncotarget.16558.

23.

Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.

Cuyàs E, Martin-Castillo B, Bosch-Barrera J, Menendez JA.

Cell Cycle. 2017 Jun 3;16(11):1022-1028. doi: 10.1080/15384101.2017.1310353. Epub 2017 Apr 7.

24.

Metformin targets histone acetylation in cancer-prone epithelial cells.

Cuyàs E, Fernández-Arroyo S, Joven J, Menendez JA.

Cell Cycle. 2016 Dec 16;15(24):3355-3361. doi: 10.1080/15384101.2016.1249547. Epub 2016 Oct 28.

25.

STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer.

Cuyàs E, Pérez-Sánchez A, Micol V, Menendez JA, Bosch-Barrera J.

Cell Cycle. 2016 Dec 16;15(24):3413-3418. doi: 10.1080/15384101.2016.1245249. Epub 2016 Oct 18.

26.

Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer.

Corominas-Faja B, Vellon L, Cuyàs E, Buxó M, Martin-Castillo B, Serra D, García J, Lupu R, Menendez JA.

Histol Histopathol. 2017 Jul;32(7):687-698. doi: 10.14670/HH-11-830. Epub 2016 Oct 7.

27.

Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.

Queralt B, Cuyàs E, Bosch-Barrera J, Massaguer A, de Llorens R, Martin-Castillo B, Brunet J, Salazar R, Menendez JA.

Oncotarget. 2016 Dec 13;7(50):82185-82199. doi: 10.18632/oncotarget.11985.

28.

Epigenetics and nutrition-related epidemics of metabolic diseases: Current perspectives and challenges.

Hernández-Aguilera A, Fernández-Arroyo S, Cuyàs E, Luciano-Mateo F, Cabre N, Camps J, Lopez-Miranda J, Menendez JA, Joven J.

Food Chem Toxicol. 2016 Oct;96:191-204. doi: 10.1016/j.fct.2016.08.006. Epub 2016 Aug 5. Review.

PMID:
27503834
29.

Mitophagy-driven mitochondrial rejuvenation regulates stem cell fate.

Vazquez-Martin A, Van den Haute C, Cufí S, Corominas-Faja B, Cuyàs E, Lopez-Bonet E, Rodriguez-Gallego E, Fernández-Arroyo S, Joven J, Baekelandt V, Menendez JA.

Aging (Albany NY). 2016 Jul;8(7):1330-52. doi: 10.18632/aging.100976.

30.

Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based "starvation" strategies in BRCA1 carriers.

Cuyàs E, Fernández-Arroyo S, Alarcón T, Lupu R, Joven J, Menendez JA.

Oncotarget. 2016 Aug 16;7(33):52974-52992. doi: 10.18632/oncotarget.9732.

31.

Suppression of endogenous lipogenesis induces reversion of the malignant phenotype and normalized differentiation in breast cancer.

Gonzalez-Guerrico AM, Espinoza I, Schroeder B, Park CH, Kvp CM, Khurana A, Corominas-Faja B, Cuyàs E, Alarcón T, Kleer C, Menendez JA, Lupu R.

Oncotarget. 2016 Nov 1;7(44):71151-71168. doi: 10.18632/oncotarget.9463.

32.

Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin.

Bosch-Barrera J, Sais E, Cañete N, Marruecos J, Cuyàs E, Izquierdo A, Porta R, Haro M, Brunet J, Pedraza S, Menendez JA.

Oncotarget. 2016 May 31;7(22):32006-14. doi: 10.18632/oncotarget.7900.

33.

Accelerated geroncogenesis in hereditary breast-ovarian cancer syndrome.

Menendez JA, Folguera-Blasco N, Cuyàs E, Fernández-Arroyo S, Joven J, Alarcón T.

Oncotarget. 2016 Mar 15;7(11):11959-71. doi: 10.18632/oncotarget.7867.

34.

Activation of the methylation cycle in cells reprogrammed into a stem cell-like state.

Fernández-Arroyo S, Cuyàs E, Bosch-Barrera J, Alarcón T, Joven J, Menendez JA.

Oncoscience. 2016 Jan 5;2(12):958-967. eCollection 2015.

35.

Oncometabolic Nuclear Reprogramming of Cancer Stemness.

Menendez JA, Corominas-Faja B, Cuyàs E, García MG, Fernández-Arroyo S, Fernández AF, Joven J, Fraga MF, Alarcón T.

Stem Cell Reports. 2016 Mar 8;6(3):273-83. doi: 10.1016/j.stemcr.2015.12.012. Epub 2016 Feb 11.

36.

Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.

Martin-Castillo B, Lopez-Bonet E, Cuyàs E, Viñas G, Pernas S, Dorca J, Menendez JA.

Oncotarget. 2015 Oct 20;6(32):32317-38. doi: 10.18632/oncotarget.6094.

37.

Exploring the Process of Energy Generation in Pathophysiology by Targeted Metabolomics: Performance of a Simple and Quantitative Method.

Riera-Borrull M, Rodríguez-Gallego E, Hernández-Aguilera A, Luciano F, Ras R, Cuyàs E, Camps J, Segura-Carretero A, Menendez JA, Joven J, Fernández-Arroyo S.

J Am Soc Mass Spectrom. 2016 Jan;27(1):168-77. doi: 10.1007/s13361-015-1262-3. Epub 2015 Sep 17.

PMID:
26383735
38.

Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype.

Cuyàs E, Fernández-Arroyo S, Corominas-Faja B, Rodríguez-Gallego E, Bosch-Barrera J, Martin-Castillo B, De Llorens R, Joven J, Menendez JA.

Oncotarget. 2015 May 20;6(14):12279-96.

39.

Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties.

Cuyàs E, Martin-Castillo B, Corominas-Faja B, Massaguer A, Bosch-Barrera J, Menendez JA.

Cell Cycle. 2015;14(22):3527-32. doi: 10.1080/15384101.2015.1044173.

40.

Metabostemness: Metaboloepigenetic reprogramming of cancer stem-cell functions.

Menendez JA, Corominas-Faja B, Cuyàs E, Alarcón T.

Oncoscience. 2014 Dec 26;1(12):803-6. eCollection 2014.

41.

Active transmembrane drug transport in microgravity: a validation study using an ABC transporter model.

Vaquer S, Cuyàs E, Rabadán A, González A, Fenollosa F, de la Torre R.

F1000Res. 2014 Aug 21;3:201. doi: 10.12688/f1000research.4909.1. eCollection 2014.

42.

Computer-aided discovery of biological activity spectra for anti-aging and anti-cancer olive oil oleuropeins.

Corominas-Faja B, Santangelo E, Cuyàs E, Micol V, Joven J, Ariza X, Segura-Carretero A, García J, Menendez JA.

Aging (Albany NY). 2014 Sep;6(9):731-41.

43.

Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells.

Corominas-Faja B, Cuyàs E, Gumuzio J, Bosch-Barrera J, Leis O, Martin ÁG, Menendez JA.

Oncotarget. 2014 Sep 30;5(18):8306-16.

44.

Silibinin administration improves hepatic failure due to extensive liver infiltration in a breast cancer patient.

Bosch-Barrera J, Corominas-Faja B, Cuyàs E, Martin-Castillo B, Brunet J, Menendez JA.

Anticancer Res. 2014 Aug;34(8):4323-7.

PMID:
25075066
45.

The nutritional phenome of EMT-induced cancer stem-like cells.

Cuyàs E, Corominas-Faja B, Menendez JA.

Oncotarget. 2014 Jun 30;5(12):3970-82.

46.

Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment.

Menendez JA, Quirantes-Piné R, Rodríguez-Gallego E, Cufí S, Corominas-Faja B, Cuyàs E, Bosch-Barrera J, Martin-Castillo B, Segura-Carretero A, Joven J.

Oncotarget. 2014 May 15;5(9):2344-8.

47.

Cell cycle regulation by the nutrient-sensing mammalian target of rapamycin (mTOR) pathway.

Cuyàs E, Corominas-Faja B, Joven J, Menendez JA.

Methods Mol Biol. 2014;1170:113-44. doi: 10.1007/978-1-4939-0888-2_7. Review.

PMID:
24906312
48.

Discovery and validation of an INflammatory PROtein-driven GAstric cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics.

Puig-Costa M, Codina-Cazador A, Cortés-Pastoret E, Oliveras-Ferraros C, Cufí S, Flaquer S, Llopis-Puigmarti F, Pujol-Amado E, Corominas-Faja B, Cuyàs E, Ortiz R, Lopez-Bonet E, Queralt B, Guardeño R, Martin-Castillo B, Roig J, Joven J, Menendez JA.

Oncotarget. 2014 Apr 15;5(7):1942-54.

49.

Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile.

Oliveras-Ferraros C, Vazquez-Martin A, Cuyàs E, Corominas-Faja B, Rodríguez-Gallego E, Fernández-Arroyo S, Martin-Castillo B, Joven J, Menendez JA.

Cell Cycle. 2014;13(7):1132-44. doi: 10.4161/cc.27982. Epub 2014 Feb 7.

50.

Xenopatients 2.0: reprogramming the epigenetic landscapes of patient-derived cancer genomes.

Menendez JA, Alarcón T, Corominas-Faja B, Cuyàs E, López-Bonet E, Martin AG, Vellon L.

Cell Cycle. 2014;13(3):358-70. doi: 10.4161/cc.27770. Epub 2014 Jan 9.

Supplemental Content

Support Center